New developments and strategies for success in dealing with FDA, OIG, SEC, EMEA, and more.
February 1, 2012
By:Jill Wechsler
Will expanded markets and ACOs offset higher rebates, added fees, and closer scrutiny of marketing and prices?
 |
February 1, 2012
By:Jennifer Ringler
Experts weigh in on FDA's long-awaited social media guidelines.
|
January 1, 2012
By:Christopher J. Piazza
A key consideration under the Affordable Care Act is how states select plans for drug coverage.
|
January 1, 2012
By:Jill Wechsler
Look for action in 2012 on drug access, shortages, innovation, and transparency.
|
December 1, 2011
By:Lujing Wang
Thorough risk assessment is essential before placing bets on good evidence that clears a path to approval.
|
November 1, 2011
With OTCs challenging traditional approaches to quality, new opportunities are arising to support industry innovation and advance public health.
|
November 1, 2011
By:Jill Wechsler
Clamor for critical therapies prompts probes of prices, production practices.
|
October 1, 2011
By:Jill Wechsler
Janet Woodcock, MD, Director, FDA Center for Drug Evaluation and Research
|
| 
PharmExec Blog
Follow Us
RSS
Bookstore
